Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Timing matters: when to first assess symptoms in UC treatment?

NCT ID NCT06998693

Knowledge-focused Sponsor: Xijing Hospital of Digestive Diseases Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study from Xijing Hospital looked at 180 adults with mild-to-moderate ulcerative colitis starting 5-ASA therapy. Researchers compared checking symptoms at 4, 8, or 12 weeks to see which timing best predicted treatment success at 48 weeks. The goal was to help doctors personalize treatment decisions by identifying early responders and non-responders.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
5-ASA (mesalazine)
What this could lead to
If successful, this study could help doctors know when to first check symptoms to better tailor 5-ASA treatment for ulcerative colitis patients.
What could go wrong
This is an observational study, not a treatment trial, so it won't prove a new therapy works. Results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

180 people

The number who actually took part.

Started

Aug 2024

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study aims to compare the impact of the time point of the first assessment of patients (4th, 8th, and 12th weeks) on the short-term efficacy of 5-ASA on ulcerative colitis. The patients are divided into three groups: the 4-week assessment group, the 8-week assessment group, and the 12-week assessment group, with 60 patients in each group, totaling 180 patients.

Ages

18 to 59 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. According to the diagnostic criteria of the China's 2023 Consensus Opinion on the Diagnosis and Treatment of Inflammatory Bowel Disease, the disease status is newly diagnosed ulcerative colitis (UC) or mild to moderate active UC with remission followed by recurrence (modified Mayo score 3-10 points); 2. Age: 18-59 years old; 3. The attending physician will propose an oral mesalazine or an oral w/ topical mesalazine combined treatment plan based on the patient's condition; 4. Patients who are abble to and are willing to comply with the research protocol can provide a signed and dated written informed consent form. Exclusion Criteria: 1. Use any form of hormone within the past 14 days; 2. Have received immunosuppressive therapy within the past 90 days; 3. Have used infliximab, adalimumab, or vedolizumab within the past 60 days; 4. Have taken anti-diarrheal drugs within the past 3 days; 5. Have participated in any clinical trial within the past 3 months; 6. Allergic to mesalazine or salicylic acid preparations (except sulfasalazine), including severe adverse reactions, liver and kidney diseases, heart and lung diseases, malignant tumors, etc.; 7. Have had severe liver and kidney diseases, heart and lung diseases, hematological diseases and pancreatic diseases in the past; 8. Pregnant or lactating women; 9. Patients who have withdrawn their informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UL are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ulcerative colitis uterine corpus leiomyoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UL

Contacts and locations

Locations

  • Xijing Hospital of Digestive Diseases

    Xi'an, Shaanxi, 710032, China